China Drug Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts

The China Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps, and More), Route of Administration (Injectable, Inhalational, Transdermal, and More), Therapeutic Application (Cardiovascular, Oncology, Diabetes, and More), and Sales Channel (Hospitals, Offline Pharmacies, and More). The Market Forecasts are Provided in Terms of Value (USD).

China Drug Delivery Devices Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
View Global Report

Compare market size and growth of China Drug Delivery Devices Market with other markets in Healthcare Industry

China Drug Delivery Devices Market Analysis by Mordor Intelligence

The China drug delivery devices market is valued at USD 13.65 billion in 2025 and is forecast to reach USD 20.92 billion by 2030, registering an 8.92% CAGR over the period. Growth is powered by a rapidly aging population, 28% of citizens will be over 60 by 2040, along with rising chronic-disease prevalence, sweeping reimbursement reforms, and a wave of biologics that demand precision delivery.[1]World Health Organization, “Ageing and health – China,” who.int Volume-Based Procurement (VBP) has lowered average drug prices by 53%, which is steering hospitals toward locally made devices while encouraging global suppliers to localize production. Persistent air-quality challenges in tier-1 cities are sustaining demand for inhalation platforms even as respiratory conditions remain a public-health priority. At the same time, 5G connectivity and AI-enabled adherence tools are opening fresh opportunities for smart, home-use systems in rural regions.[2]National Healthcare Security Administration, “China Focus: National medical insurance delivers more,” english.news.cn Competitive pressure is intensifying as domestic contract development and manufacturing organizations (CDMOs) scale up, compressing costs for both injectables and emerging implantables. 

Key Report Takeaways

  • By device type, injectable platforms led with a 42.34% revenue share in 2024, while implantable systems are projected to expand at an 11.33% CAGR to 2030.
  • By route of administration, injectable routes accounted for 48.65% of the China drug delivery devices market share in 2024, whereas ocular delivery is forecast to post a 10.78% CAGR through 2030.
  • By therapeutic application, oncology captured 29.46% of the China drug delivery devices market size in 2024, while diabetes devices are set to grow at a 9.66% CAGR to 2030.
  • By sales channel, hospitals held 57.89% revenue share in 2024; online pharmacies record the highest projected CAGR at 12.06% through 2030.

Segment Analysis

By Device Type: Injectable Devices Lead Market Transformation

Injectable platforms retained a 42.34% share in 2024, anchoring the China drug delivery devices market as hospitals prefer proven parenteral formats for biologics and vaccines. Implantables post the fastest 11.33% CAGR, benefiting from materials science advances that support weeks-long release profiles. Inhalers continue to thrive in polluted metropolitan zones, while infusion pumps rise steadily on the back of ICU modernization projects. Transdermal patches win favor among seniors seeking pain relief without oral side effects, and ocular inserts gain momentum as diabetic retinopathy rates climb. Nasal and buccal formats, though niche, attract pediatric demand where needle avoidance is critical. 

Injectables are also the first choice for home-based biologic regimens, which tightens linkages between prefilled syringe makers and tele-pharma platforms. Meanwhile, implantables ride on gene-therapy momentum: start-ups in Shanghai are prototyping refillable micro-reservoirs to pair with autologous cell payloads. These trends reinforce the China drug delivery devices market size leadership of injectable formats, yet implantables are closing the gap as payers recognize reduced dosing frequency benefits. 

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Route of Administration: Injectable Routes Dominate Therapeutic Delivery

With 48.65% of 2024 revenue, injectables remain the backbone of therapeutic delivery owing to unmatched bioavailability and multi-therapeutic flexibility. Ocular routes, however, show a 10.78% CAGR through 2030 as sustained-release implants cut injection frequency for macular degeneration. Inhalation stands firm because pollution-driven chronic obstructive pulmonary disease (COPD) cases remain high in urban clusters. Transdermal lines grow in cardiovascular care, aided by skin-friendly adhesives that enable week-long nitroglycerin delivery. Oral mucosal and nasal routes gain share for emergency and pediatric uses where rapid onset is pivotal. 

Regulators now encourage patient-reported outcomes in ocular trials, fast-tracking approvals for micro-dose injectors that limit systemic exposure. Local inhaler makers add smartphone pairing to monitor technique, meeting NHSA evidence thresholds for reimbursement. As a result, the China drug delivery devices market share of non-injectable routes is set to widen, although injectables keep pole position for biologics and vaccines. 

By Therapeutic Application: Oncology Leadership Amid Diabetes Surge

Oncology captured 29.46% revenue in 2024, reflecting heavy R&D spending by firms like BeiGene on targeted antibodies requiring specialized delivery. Diabetes devices are projected to clock a 9.66% CAGR as the country grapples with its vast diabetic population. Cardiovascular applications stay prominent given 330 million affected patients, while autoimmune therapies benefit from biologics entering NHSA coverage. Pulmonary indications tap pollution-linked disease burden, and neurology sees steady growth as Alzheimer’s detection rises. Gene-therapy deliveries remain small but climb quickly due to landmark financings in 2024. 

Oncology players innovate with subcutaneous on-body injectors that deliver multi-hour infusions at home, easing hospital load. Diabetes interprets smart-pen and patch-pump ecosystems to bolster adherence, aligning with Healthy China guidelines. Consequently, diabetes stands ready to challenge oncology’s dominance as connected dosage tracking proves cost-effective for payers. 

Market Segment share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Sales Channel: Hospital Dominance Challenged by Digital Transformation

Hospitals controlled 57.89% of 2024 sales, mirroring China’s institutional care model and complex device calibration needs. Online pharmacies, though smaller, will log a 12.06% CAGR on the back of e-prescription policy liberalization and telehealth uptake. Brick-and-mortar pharmacies fill gaps in tier-2 cities and handle immediate pickup for chronic prescriptions, while specialty clinics and home-health services join distribution chains as payers push care closer to patients. 

VBP policies now apply across channels, so online retailers compete on logistics and adherence services instead of price. Hospitals, meanwhile, integrate 5G pumps into electronic medical records, giving them an edge in bundled outcome contracts. Over time, device makers will refine packaging and user interfaces for direct-to-patient supply, nurturing a multi-channel China drug delivery devices market size dynamic. 

market segment share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

Tier-1 cities—Beijing, Shanghai, Guangzhou, and Shenzhen—set adoption benchmarks owing to higher incomes, dense hospital networks, and early access to NMPA-approved innovations. Pollution remains acute, sustaining premium inhaler uptake, while provincial tenders in these hubs often become bellwethers for national reimbursement. Tier-2/3 cities such as Chengdu and Wuhan post faster growth as infrastructure builds out and NHSA reimbursement boosts affordability. Cold-chain gaps remain a hurdle but also spur investment in passive cooling and temperature-stable formulations. 

Rural regions, despite thin provider density, offer long-term volume upside thanks to Healthy China mandates focused on equity. Portable injectors and connected patches are attractive here because they minimize clinic visits. County-wide 5G pilots in Shanxi cut adherence lapses, illustrating how connectivity can offset staff shortages. Domestic manufacturers in Jiangsu and Guangdong leverage proximity to export ports and skilled labour to scale production that feeds both coastal and inland demand. 

Regional supply chains now feature vertically integrated parks that cluster molding, sterilization, and packaging within a single free-trade zone, trimming lead times to western provinces by up to 30%. As such ecosystems mature, the China drug delivery devices market is expected to show narrowing regional price differentials while premium adoption still skews east. 

Competitive Landscape

Global suppliers such as Becton Dickinson, Gerresheimer and Pfizer still anchor high-value tiers, yet their pricing leverage is shrinking as Volume-Based Procurement forces local manufacturing and leaner cost structures. Becton Dickinson has expanded syringe capacity in Suzhou to secure future bulk tenders for prefilled systems npe.org. Gerresheimer entered a Shandong joint venture that shortens lead times on moulded glass vials for provincial reimbursement cycles. Pfizer now packages oncology kits in Zhejiang to keep cold-chain logistics entirely within China. Together, these moves underline how multinationals are recalibrating footprints to stay price-competitive.

Domestic champions are scaling quickly on the back of integrated campuses and targeted R&D. Weigao Group lifted revenue to RMB 10.36 billion after opening a Weihai complex that cuts syringe unit cost by nearly 20%. MicroPort leveraged its cardiology franchise to launch the Firelimus drug-eluting balloon in 2025, positioning the product as a home-grown alternative to imported stents. Keymed Biosciences gained supplemental approval for Stapokibart and paired the antibody with a proprietary prefilled pen to reduce clinic visits for chronic rhinosinusitis. These successes show how local innovators marry rapid regulatory navigation with cost advantages.

Investment remains brisk even as compliance costs climb. METiS Pharmaceuticals raised USD 100 million for AI-guided lipid nanoparticle platforms aimed at mRNA and cell therapies, signalling strong appetite for next-generation delivery science. Contract development and manufacturing hubs in Jiangsu and Guangdong provide turnkey scale for start-ups that lack capex headroom. Rising capital intensity is nudging smaller firms toward mergers, pointing to gradual consolidation around players that combine local cost bases with clinically verified performance.

China Drug Delivery Devices Industry Leaders

  1. Becton, Dickinson and Company

  2. Gerresheimer AG

  3. Pfizer Inc.

  4. Kindly Medical Instruments Co., Ltd

  5. Ypsomed Holding AG

  6. *Disclaimer: Major Players sorted in no particular order
China Drug Delivery Devices Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • February 2025: MicroPort’s Firelimus Rapamycin Drug-Eluting Balloon Catheter gained NMPA approval for coronary bifurcation lesions, offering an excipient-free alternative to permanent stents.
  • January 2025: NHSA added 91 drugs to reimbursement with 63% price cuts, saving USD 7.6 billion and widening access to advanced delivery systems.
  • December 2024: Keymed Biosciences received sNDA approval for Stapokibart to treat chronic rhinosinusitis with nasal polyposis.
  • September 2024: Regeneron and Sanofi secured NMPA clearance for Dupixent as add-on COPD therapy, marketed in 300 mg pre-filled devices.

Table of Contents for China Drug Delivery Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Chronic Diseases
    • 4.2.2 Advances in Biologics Necessitating Sophisticated Devices
    • 4.2.3 Government Health‐Insurance Expansion
    • 4.2.4 Urban Air-Quality Decline Boosting Inhalation Demand
    • 4.2.5 Domestic CDMO Scale-up Lowering Device Costs
    • 4.2.6 5G-enabled Smart Connectivity for Adherence Monitoring
  • 4.3 Market Restraints
    • 4.3.1 High R&D and Approval Costs
    • 4.3.2 Centralized Volume-based Procurement (VBP) Price Pressure
    • 4.3.3 Cold-chain Gaps in Lower-tier Cities
    • 4.3.4 Fragmented IP Landscape Delaying Innovation
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technology Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value-USD)

  • 5.1 By Device Type
    • 5.1.1 Injectable Delivery Devices
    • 5.1.2 Inhalation Delivery Devices
    • 5.1.3 Infusion Pumps
    • 5.1.4 Transdermal Patches
    • 5.1.5 Implantable Drug Delivery Systems
    • 5.1.6 Ocular Inserts & Delivery Implants
    • 5.1.7 Nasal & Buccal Delivery Devices
  • 5.2 By Route of Administration
    • 5.2.1 Injectable
    • 5.2.2 Inhalation
    • 5.2.3 Transdermal
    • 5.2.4 Oral Mucosal (Buccal & Sublingual)
    • 5.2.5 Ocular
    • 5.2.6 Nasal
  • 5.3 By Therapeutic Application
    • 5.3.1 Cardiovascular
    • 5.3.2 Oncology
    • 5.3.3 Autoimmune Disorders
    • 5.3.4 Pulmonary Diseases
    • 5.3.5 Diabetes
    • 5.3.6 Neurological Disorders
    • 5.3.7 Other Applications
  • 5.4 By Sales Channel
    • 5.4.1 Hospitals
    • 5.4.2 Offline Pharmacies
    • 5.4.3 Online Pharmacies
    • 5.4.4 Other Channels

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
    • 6.3.1 Becton, Dickinson and Company
    • 6.3.2 Gerresheimer AG
    • 6.3.3 Pfizer Inc.
    • 6.3.4 Teleflex Medical
    • 6.3.5 Teva Pharmaceutical Industries Ltd.
    • 6.3.6 Organon
    • 6.3.7 Novartis AG
    • 6.3.8 GSK plc
    • 6.3.9 Baxter International Inc.
    • 6.3.10 Ypsomed Holding AG
    • 6.3.11 Kindly Medical Instruments Co., Ltd.
    • 6.3.12 Jiangsu Delfu Medical Device Co., Ltd.
    • 6.3.13 MicroPort Scientific Corporation
    • 6.3.14 Shanghai Pukun Medical Co., Ltd.
    • 6.3.15 SHL Medical AG
    • 6.3.16 Tianjin Pharmaco Medical Devices Co., Ltd.
    • 6.3.17 Nemera
    • 6.3.18 Owen Mumford Ltd.
    • 6.3.19 Elcam Medical

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

China Drug Delivery Devices Market Report Scope

As per the scope of the report, drug delivery devices are specialized tools for delivering a drug or therapeutic agent via a specific route of administration.

The Chinese drug delivery devices market is segmented by device type, therapeutic application, and sales channel. By device type, the market is segmented into nasal, implantable, injectable, and other device types. The nasal segment includes inhalers and other device types. The injectable segment includes conventional drug delivery devices and self-injectable drug delivery devices. Self-injectable drug delivery devices include prefilled syringes, auto-injectors, and other self-injectable drug delivery devices. The other device types include droppers and sprays. By therapeutic application, the market is segmented into cardiovascular, oncology, autoimmune disorder, pulmonary disease, and other therapeutic applications. Other therapeutic applications include metabolic diseases, infectious diseases, and others. By sales channel, the market is segmented into hospitals, pharmacies, and other sales channels. The other sales channels include clinics, ambulatory centers, and others. The report offers market sizes and forecasts in terms of value (USD) for the above segments.

By Device Type Injectable Delivery Devices
Inhalation Delivery Devices
Infusion Pumps
Transdermal Patches
Implantable Drug Delivery Systems
Ocular Inserts & Delivery Implants
Nasal & Buccal Delivery Devices
By Route of Administration Injectable
Inhalation
Transdermal
Oral Mucosal (Buccal & Sublingual)
Ocular
Nasal
By Therapeutic Application Cardiovascular
Oncology
Autoimmune Disorders
Pulmonary Diseases
Diabetes
Neurological Disorders
Other Applications
By Sales Channel Hospitals
Offline Pharmacies
Online Pharmacies
Other Channels
By Device Type
Injectable Delivery Devices
Inhalation Delivery Devices
Infusion Pumps
Transdermal Patches
Implantable Drug Delivery Systems
Ocular Inserts & Delivery Implants
Nasal & Buccal Delivery Devices
By Route of Administration
Injectable
Inhalation
Transdermal
Oral Mucosal (Buccal & Sublingual)
Ocular
Nasal
By Therapeutic Application
Cardiovascular
Oncology
Autoimmune Disorders
Pulmonary Diseases
Diabetes
Neurological Disorders
Other Applications
By Sales Channel
Hospitals
Offline Pharmacies
Online Pharmacies
Other Channels
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

1. What is the current size of the China drug delivery devices market and how fast is it growing?

The market stands at USD 13.65 billion in 2025 and is projected to expand to USD 20.92 billion by 2030, reflecting an 8.92% CAGR.

2. Which device segment is expanding the quickest?

Implantable drug delivery systems show the fastest momentum, advancing at an 11.33% CAGR through 2030 on the back of long-acting therapies and aging-related demand.

3. How is Volume-Based Procurement (VBP) influencing device pricing?

VBP rounds have driven average drug-price cuts of 53%, compelling manufacturers to lower device costs and favoring suppliers with local production footprints.

4. Why are inhalation devices in strong demand despite pollution improvements?

Tier-1 city air-quality levels remain 5.6 times above WHO guidelines, sustaining a large respiratory patient pool that requires advanced inhaler platforms.

5. What role does 5G connectivity play in China’s drug delivery devices landscape?

More than 94,000 commercial 5G cases enable real-time adherence monitoring, particularly boosting uptake of smart infusion pumps and connected insulin pens in underserved areas.

6. Which restraint poses the greatest challenge for new entrants?

High R&D and regulatory-approval costs, intensified by stricter NMPA testing requirements, represent the steepest barrier, cutting most sharply into smaller manufacturers’ margins.

Page last updated on: June 11, 2025

China Drug Delivery Devices Market Report Snapshots